Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification

BACKGROUND: Cerebrospinal fluid biomarker profiles characterized by decreased amyloid-beta peptide levels and increased total and phosphorylated tau levels at threonine 181 (pT181) are currently used to discriminate between Alzheimer’s disease and other neurodegenerative diseases. However, these cha...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Alzheimers Res Ther
Egile Nagusiak: Barthélemy, Nicolas R., Bateman, Randall J., Hirtz, Christophe, Marin, Philippe, Becher, François, Sato, Chihiro, Gabelle, Audrey, Lehmann, Sylvain
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2020
Gaiak:
Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7079453/
https://ncbi.nlm.nih.gov/pubmed/32183883
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13195-020-00596-4
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak